Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Change in Accured Expenses (2019 - 2025)

Keros Therapeutics filings provide 7 years of Change in Accured Expenses readings, the most recent being -$4.4 million for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 241.03% to -$4.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$10.1 million, a 443.19% decrease, with the full-year FY2025 number at -$10.1 million, down 443.19% from a year prior.
  • Change in Accured Expenses hit -$4.4 million in Q4 2025 for Keros Therapeutics, up from -$4.8 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $8.7 million in Q3 2024 to a low of -$5.4 million in Q1 2024.
  • Median Change in Accured Expenses over the past 5 years was $317500.0 (2022), compared with a mean of $302600.0.
  • Biggest five-year swings in Change in Accured Expenses: surged 4494.85% in 2022 and later tumbled 647.65% in 2023.
  • Keros Therapeutics' Change in Accured Expenses stood at -$97000.0 in 2021, then surged by 4494.85% to $4.3 million in 2022, then skyrocketed by 35.75% to $5.8 million in 2023, then tumbled by 122.45% to -$1.3 million in 2024, then plummeted by 241.03% to -$4.4 million in 2025.
  • The last three reported values for Change in Accured Expenses were -$4.4 million (Q4 2025), -$4.8 million (Q3 2025), and $2.7 million (Q2 2025) per Business Quant data.